Ventyx biosciences announces dosing of the first patient in the phase 2 serenity trial of vtx958 for the treatment of moderate to severe plaque psoriasis

The phase 2 trial in psoriasis will explore a broad range of doses based on phase 1 data demonstrating class-leading safety and tyk2 target coverage

VTYX Ratings Summary

VTYX Quant Ranking